ArticleAdvances in therapy2026
Safety and Effectiveness of Guanfacine Hydrochloride Extended-Release in Adult Patients with ADHD in Japan: A Post-Marketing Surveillance Study.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis post-marketing surveillance study assessed the safety and effectiveness of guanfacine hydrochloride extended-release (GXR) in adults with attention-deficit/hyperactivity disorder (ADHD) in routine clinical practice in Japan.
methodsIn this prospective, multicenter study, adults (≥ 18 years) were followed for 1 year after initiating GXR treatment or until treatment discontinuation, whichever occurred first (enrollment: June 2020-March 2022). Hypotension and bradycardia, syncope, blood pressure elevation upon discontinuation, and QT prolongation were key safety concerns for evaluation. Missing data were not imputed; therefore, effectiveness outcomes reflect only the observed data.
resultsIn total, 961 patients were enrolled across 155 sites; case report forms were collected for 949 patients. Of these, 912 and 784 were included in the safety and effectiveness analyses, respectively. The 12-month GXR continuation rate was 45.2%. Adverse drug reactions (ADRs) reported in ≥ 1% of patients were somnolence (15.02%), dizziness (3.95%), malaise (3.73%), postural dizziness (2.85%), thirst (2.52%), decreased blood pressure (1.86%), hypotension (1.54%), and constipation (1.43%). Seventeen serious ADRs occurred in 13 patients: bradycardia, cerebral ischemia, mental impairment, and syncope (n = 2 each) and decreased blood pressure, delusions, dizziness, postural dizziness, erectile dysfunction, hallucination, psychomotor hyperactivity, somnolence, and suicidal ideation (n = 1 each). Forty-one patients (4.50%) experienced 42 hypotension and bradycardia events (3 were serious). Two patients (0.22%) experienced a syncope event (preferred term: syncope); although both were assessed as non-serious by the investigator, they were classified as serious per the Important Medical Events list. In accordance with the Japanese Risk Management Plan, these two events were also recorded as QT prolongation events (preferred term: syncope). Improvement rates in Clinical Global Impression-Improvement and Patient Global Impression-Improvement scales increased over the 1-year observation period. ADHD-Rating Scale-IV total and subscale scores also improved over time, with significant improvements from baseline observed at all time points (p < 0.0001).
conclusionsNo ADRs requiring new safety measures were observed. The effectiveness of GXR in adult ADHD was evident among patients remaining on treatment.
trial registrationUMIN Clinical Trials Registry (identifier: UMIN000040429).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.